Bionomics Approves The Proposed Scheme Of Arrangement In Relation To The Company's Proposed Re-Domiciliation From Australia To The U.S., Under Which Neuphoria Therapeutics, Will Become The Ultimate Parent Company Of Bionomics
Bionomics Approves The Proposed Scheme Of Arrangement In Relation To The Company's Proposed Re-Domiciliation From Australia To The U.S., Under Which Neuphoria Therapeutics, Will Become The Ultimate Parent Company Of Bionomics
Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States.
Bionomics Limited（纳斯达克股票代码：BNOX）（“Bionomics” 或 “公司”）很高兴就其拟议从澳大利亚迁往美国的注册情况提供以下最新情况。
Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement.
Bionomics股东今天以必要多数批准了与该公司提议从澳大利亚迁往美国的拟议安排计划，根据该安排，特拉华州的一家公司Neuphoria Therapeutics Inc.（“Neuphoria”）将在协议计划实施后成为Bionomics Limited的最终母公司。
